Role of osteocytes in multiple myeloma bone disease.
Role of osteocytes in multiple myeloma bone disease.
复制标题
DOI：
10.1097/spc.0000000000000090
复制
发表时间：
2014-12
影响因子：
2.1
通讯作者：
Roodman GD
中科院分区：
文献类型：
--
作者：
Delgado-Calle J;Bellido T;Roodman GD
尽管人们对骨细胞生物学的了解不断增加，但这种最丰富的骨细胞对骨中多发性骨髓瘤的发生和进展的贡献实际上尚未被探索。多发性骨髓瘤骨病的特征是骨吸收加剧和溶骨性病变的存在，该病变由于骨形成的伴随减少而无法愈合。骨细胞产生调节骨形成和骨吸收的分子。最近的研究结果表明，患有骨病变的多发性骨髓瘤患者的骨细胞寿命受到损害。此外，多发性骨髓瘤细胞通过上调促破骨细胞因子的产生、刺激破骨细胞的形成和活性来影响骨细胞的转录谱。此外，患有活动性多发性骨髓瘤的患者的硬化素的循环水平升高，硬化素是骨形成的有效抑制剂，由骨中的骨细胞特异性表达。了解骨细胞对多发性骨髓瘤骨病骨骼后果机制的贡献有可能提供专门针对多发性骨髓瘤-骨细胞相互作用的重要的新治疗策略。
Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored. Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of pro-osteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone. Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma–osteocyte interactions.